Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Sarcoma 2Osteosarcoma 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Biphenotypic, Acute 2Unspecified Adult Solid Tumor, Protocol Specific 1Sezary Syndrome 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Hypersensitivity 1Dendritic Cell Sarcoma, Interdigitating 1Degradation of Top2b and Top2a in Human by Dexrazoxane 1Cardiotoxicity 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

oblimersen 1Razoxane 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Exercise 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Carvedilol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cardiotoxicity × Dexrazoxane × Clear all
NCT00039481 2013-01-17

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡